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Cyclooxygenase-2 is the rate-limiting enzyme in synthesis of prostaglandins and other eicosanoids. Prior reports have shown
that inhibition of cyclooxygenase-2 activity, either by selective inhibitors or by antisense oligonucleotide, results in suppression
of growth of squamous cell carcinoma cell lines which express high cyclooxygenase-2 levels, such as NA, a cell line established
from a squamous cell carcinoma of the tongue. To investigate the mechanisms by which cyclooxygenase-2 inhibitors
suppressed growth of these cells, the effects of NS-398, the selective cyclooxygenase-2 inhibitor, on cell-cycle distribution
were examined. NS-398 induced G0/G1 cell-cycle arrest in NA cells which expressed cyclooxygenase-2. G0/G1 arrest
induced by NS-398 was accompanied by up-regulation of cyclin-dependent kinase inhibitor p21, but not by up-regulation of
the other cyclin-dependent kinase inhibitors. Transfection with p21 antisense oligonucleotide inhibited cell-cycle arrest induced
by NS-398. Accumulation in G0/G1 was also observed in NA cells transfected with cyclooxygenase-2 antisense
oligonucleotide. On the other hand, NS-398-treated NA cells showed a loss of plasma membrane asymmetry, a marker
of early events in apoptosis. However, NS-398 did not induce other morphological and biochemical changes related to
apoptotic cell death. These results suggest that cyclooxygenase-2 inhibitor induces G0/G1 cell-cycle arrest in NA cells by up-
regulation of p21. Our results also suggest that NS-398 is not sufﬁcient to complete the whole process of apoptosis in NA
cells, although it induces an early event in apoptosis.
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Prostaglandin endoperoxide H synthase (also referred to as
cyclooxygenase (COX)) is the rate-limiting enzyme in the produc-
tion of prostaglandins (PG) and thromboxanes, which are involved
in various physiologic and pathologic processes such as inﬂamma-
tion, angiogenesis and development of cancer. Two COX isoforms
(COX-1 and COX-2) that differ signiﬁcantly in their patterns of
expression have been identiﬁed (Kujubu et al, 1991; Xie et al,
1991; Hla and Neilson, 1992; O’Banion et al, 1991; Williams and
Shacter, 1997). COX-1 is constitutively expressed in many tissues
and cells, including the gastric mucosa (Smith et al, 1993; Williams
and DuBois, 1996). By contrast, COX-2 is an immediate, early
response gene expressed at very low levels unless induced by mito-
gens (Lee et al, 1992), cytokines (Maier et al, 1990), and tumour
promoters (Kujubu et al, 1991). After these stimulations, cells
expressing COX-2 synthesise and release large amount of prosta-
noids. These COX isoforms have both overlapping as well as
distinct physiologic and pathologic functions (Hia et al, 1993;
Dubois et al, 1998). While COX-1 is involved in the homeostasis
of various physiologic functions, COX-2 is responsible for many
inﬂammatory processes. Both COX enzymes catalyse two distinct
reactions: (1) conversion of arachidonic acid to PGG2 via the
cyclooxygenase activity and (2) the reduction of PGG2 to PGH2
via the peroxidase activity. PGH2 is converted by distinct
isomerases into biologically active PGs, including PGD2 and
PGE2. Nonsteroidal anti-inﬂammatory drugs such as aspirin and
indomethacin inhibit the cyclooxygenase activity, but not the
peroxide activity (Lahenville et al, 1994; Smith and Dewitt,
1996). Recently, inhibitors which selectively inhibit COX-2 activity
have been made (Taketo, 1998a,b). These inhibitors, for example
NS-398, inhibit the cyclooxygenase activity of COX-2 and thus
inhibit prostanoid synthesis (Warner et al, 1999).
It is reported that greater than 80% of colon cancers in humans
have increased COX-2 levels when compared to adjacent normal
tissue (Williams et al, 1997), and overexpression of COX-2 has
been identiﬁed as an early central event in colon carcinogenesis
(Kargman et al, 1995; Tsuji and Dubois, 1995; Boolbol et al,
1996; Reddy et al, 1996; Tsuji et al, 1997). Previous studies have
also demonstrated that constitutive expression of COX-2 in human
colon cancer cells promotes tumour invasion and the metastatic
potential of these cells, and have suggested that COX-2 selective
inhibitors can be suitable chemopreventive agents for colorectal
cancer (Oshima et al, 1996; Tsuji et al, 1997).
As well as colorectal cancer, increased COX-2 expression is
found in carcinomas of various organs including the breast, pros-
tate (Gupta et al, 2000), lung (Wolff et al, 1998), oesophagus
(Zimmermann et al, 1999), pancreas (Tucker et al, 1999) and
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www.bjcancer.commucous membrane of head and neck (Chan et al, 1999). Thus it is
suggested that selective COX-2 inhibitors may be effective chemo-
preventive agents for these carcinomas.
Recently, we and others have shown that COX-2 selective inhi-
bitor (NS-398) inhibits proliferation of head and neck squamous
cell carcinoma (SCC) cell lines expressing COX-2 mRNA (Higashi
et al, 2000; Sumitani et al, 2001). Suppression of proliferation was
also observed in these cells transfected with COX-2 antisense oligo-
nucleotide. However, the relevant mechanisms by which COX-2
inhibition resulted in inhibition of proliferation of these cells has
not been well deﬁned. The growth inhibition in cancer cells is,
in principle, associated withdrawal from the cell cycle. The cell
cycle is regulated by proteins known as cyclins and their associated
cyclin-dependent kinases (CDKs). Mammalian cells contain at least
11 cyclins and ﬁve CDKs, and speciﬁc cyclin/CDK complexes regu-
late the different cell cycle checkpoints (Nurse 1994). One of the
most important checkpoints occurs in the late G1, just before
the start of DNA replication. D-type cyclins associate with and acti-
vate CDK2 and CDK4 proteins, which allow cells to pass this
restriction point. Loss of this cell-cycle checkpoint has been linked
to cancer, in many cases through changes in the cyclin/CDK
complexes (Hunter and Pines, 1994). More recently, a new class
of cell-cycle regulator, CDK inhibitors (CKIs), has been identiﬁed.
CKIs bind to and inhibit the activity of cyclin/CDK complexes,
resulting in the inhibition of cell-cycle progression. Two structu-
rally deﬁned classes of CKIs have been identiﬁed. The ﬁrst class,
termed the p21 family, includes p21
WAF1, p27
KIP1 and p57
KIP2,
which inhibit the activity of G1- and S phase and to a lesser extent
the mitotic cyclin/CDK complexes. The second class of CKIs,
termed the INK4 family, includes p16
INK4A, p15
INK4B, p18
INK4C
and p19
INK4D, which inhibit G1-speciﬁc cyclin D-CDK4/6 kinase
activity only.
It was reported that COX-2 inhibitor suppressed proliferation
of these cells via reduction of prostanoid production which
affected cell proliferation, tumour growth and immune respon-
siveness (Hia et al, 1993). However, COX isoforms possess a
separate peroxidase activity that can modulate other cellular
signalling pathways such as NF-kB (Munroe et al, 1995). It has
been shown that overexpression of COX-1 resulted in the tomori-
genic transformation of ECV-304 cells, and that it was not
inhibited by Indomethacin (Narko et al, 1997). Simmons and
colleagues showed that the COX-2 protein bound to an apoptosis
and autoimmunity-associated protein termed nucleobindin (Ballif
et al, 1996). These results raise the possibility that COX-2 may
regulate intercellular signalling by both PG-dependent and PG-
independent actions. In this study we examined the effects of
inhibition of COX-2, either by selective inhibitor (NS-398) or
transfection of COX-2 antisense oligonucleotide, on the cell cycle
distribution of NA, an SCC cell line established from the tongue.
The effect of NS-398 on induction of apoptosis in NA cells was
also investigated.
MATERIALS AND METHODS
Reagents and Antibodies
NS-398, a selective inhibitor of COX-2, was purchased from
Calbiochem (La Jolla, CA, USA). Nitric oxide (NO) spontaneous
donor, NOC-12, was obtained from Dojindo Laboratories (Kuma-
moto, Japan). Triton X-100 (polyoxyethylene (10) octylprenyl
ethel) was purchased from Wako Pure Chemical Industries, Ltd.
(Osaka, Japan) Phenylmethylsulphonyl ﬂuoride (PMSF), leupeptin
and approtinin were purchased from Sigma (St Louis, Missouri,
USA). Unconjugated polyclonal (p) antibodies (Ab) against the
following human antigens were used in this study: Anti-p21 pAb
(rabbit (r) immunoglobulin (Ig) G, C-19; Santa Cruz Biotechnol-
ogy, Santa Cruz, CA, USA) and p27 pAb (rIgG, N-20; Santa
Cruz Biotechnology, Santa Cruz, CA, USA).
Cell line and cell culture
NA, a cancer cell line established from a patient with SCC of the
tongue, was maintained as monolayers in Dulbecco’s modiﬁed
Eagle’s medium (DMEM) supplemented with 10% heat inactivated
foetal bovine serum (FBS), 100 u ml
71 penicillin and 100 mgm l
71
streptomycin (complete medium). Subconﬂuent monolayers of NA
cells were employed in all experiments.
Cell-cycle analysis
NA cells were trypsinized and 10
6 cells were plated. Eighteen hours
after incubation, NS-398 was added to the culture, and cells were
further incubated for 24 h. Cell cycle analysis was performed on
these cells using DNA staining and ﬂow cytometry. The cells were
washed twice with PBS, treated with 0.2% of TritonX-100 and
0.5% of RNase, and stained with 50 mgm l
71 of propidium iodide
(PI). The relative DNA content per cell was obtained by measuring
the ﬂuorescence of PI that bound stoichiometrically to DNA. The
cell cycle was analysed by ModFit LT software (Verity Software,
Inc.).
Western blot analysis
NA cells were plated in 10 ml of complete medium containing
2610
6 cells. Eighteen hours after incubation, NS-398 was added
to the culture. At 6 and 12 h after incubation, the cells were lysed
with lysis buffer (10 mM Tris-HCl (PH 7.5), 150 mM NaCl, 5 mM
EDTA, 1% TrItonX-100, 1 mM PMSF, 10 mg ml
71 Leupeptin,
20 mg ml
71 aprotinin) at 48C. After freezing and thawing three
times, insoluble material was removed by centrifugation at
15000 g for 15 min at 08C. Proteins from cell lysates (30 mg) were
separated on acrylamid-bisacrylamide-sodium dodecyl sulphate gels
in running buffer (25 mM Tris base, 192 mM glycine, 0.1% SDS)
and electrophoretically transferred to Hybond-P membranes
(Amersham Pharmacia Biotech, Buckinghamshire, UK) in transfer
buffer (25 mM Tris base, 0.19 mM glycine, 10% methanol, 0.05%
Triton X100). The membranes were blocked in blocking solution
(20 mM Tris-HCl (pH 7.4), 0.15 M NaCl, 5% nonfat dry milk)
for 1 h to overnight at room temperature. The blots were then
incubated with ﬁrst antibodies in antibody solution (20 mM Tris-
HCl (pH 7.4), 0.15 M NaCl, 0.05% Triton X-100) with gentle agita-
tion for 1 h to overnight at room temperature. After incubation
with second antibody (1:2500) for 1 h at room temperature, the
blots were determined using an ECL Western blotting kit (Amer-
sham Pharmacia Biotech, Buckinghamshire, UK), according to
the manufacturer’s instructions.
Phosphorothioate antisense oligonucleotide studies
NA cells were cultured in 10 ml of complete medium containing
5610
5 cells in the presence of p21 antisense oligonucleotides or
sense oligonucleotides (10 mM). Twenty-four hours after incuba-
tion, NA cells were cultured in the presence of NS-398 (79.5 mM)
at 378C for 24 h, and cell cycle analysis was performed as described
above.
NA cells were also incubated with COX-2 phosphorothioate
antisense or sense oligonucleotide for 24 h. The cell cycle distribu-
tion of NA cells which were transfected with COX-2 antisense
oligonucleotides (10 mM) was analysed by ﬂow cytometry, and
the results were compared to the untransfected and sense-trans-
fected NA cells. The phosphorothioate oligonucleotides used in
this study were as follows: COX-2 phosphorothioate antisense
oligonucleotide (5'-CAGTTCAGTCGAACGTTCTTTTAGTAGTAC
-3'), COX-2 phosphorothioate sense oligonucleotide (5'-GTAC-
TACTAAAAGAACGTTCGACTGAACTG -3'), p21 phosphoro-
thioate antisense oligonucleotide (5'-TCCCCAGCCGGTTCTGA-
CAT-3'), p21 phosphorothioate sense oligonucleotide (5'-
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Sapporo, Japan).
Detection of apoptosis by annexin V staining and nuclear
staining
NA cells were incubated in the presence or absence of NS-398.
Forty-eight hours after incubation, the annexin V-afﬁnity assay
and nuclear staining were performed on NA cells as described
before. Brieﬂy, NA cells were washed with binding buffer and incu-
bated with FITC-labelled annexin V in binding buffer (TACS
Annexin V-FITC kit, Trevigen, Gaitherburg, USA) for 20 min at
208C in the dark. Cells were washed three times, harvested by
gentle scraping, and resuspended in PBS with 1.5 mM Ca
2+ and
1% FBS. Cells were then ﬁxed with 4% paraformaldehyde to
prevent aggregation, and were analysed by ﬂow cytometry (FACS
Calibur, Becton-Dickinson). Data were analysed using the Cell
Quest 3.1 software. The percentage of annexin V-positive cells
was determined after setting appropriate markers for negative
and positive populations.
For assessment of the appearance of typical morphological
changes of apoptosis, staining of the cells with the DNA-speciﬁc
ﬂuorochrome bis-benzimide trihydrochloride (H33258, Calbio-
chem, La Jolla, CA, USA) was performed on NA cells. After
treatment with NS-398 for 48 h, NA cells were ﬁxed in PBS
containing 0.25% glutaraldehyde at pH 7.2, stained with
2m gm l
71 of bis-benzimide, and analysed under an inverted
ﬂuorescence microscope. Cells with condensed and fragmented
nuclei were considered apoptotic.
RESULTS
Cell-cycle analysis of NA cells treated with NS-398
We recently reported that COX-2 expression was enhanced in NA
cells, and that NS-398 suppressed proliferation of NA cells via a
PG-dependent pathway (Sumitani et al, 2001). The growth inhibi-
tory effect of NS-398 was dose-dependent. The suppression of
proliferation by NS-398 was time-dependent. It was observed to
be slight on days 1 and 2, and become obvious on days 3 and 4.
The viability of NA cells exposed to NS-398 for 4 days was
approximately 99%, as determined by trypan blue dye exclusion
assay (Sumitani et al, 2001).
To determine whether suppression of proliferation of NA cells
induced by NS-398 is associated with cell-cycle arrest, NA cells
were incubated in the presence of NS-398 for 24 h. According to
the manufacturer’s information, NS-398 at 79.5 mM selectively inhi-
bits COX-2 activity without inhibiting COX-1 activity. Therefore
NS-398 at 79.5 mM was employed in this study. The cell-cycle
distribution was then analysed by DNA staining with PI followed
by ﬂow cytometrical analysis. Treatment with NS-398 induced a
decrease in S phase population (from 31.4 to 22.0%) and a signiﬁ-
cant increase in G0/G1 population (49.3% to 73.0%), compared
with untreated NA cells (Figure 1).
Effect of NS-398 on the expression of CKIs in NA cells
The cell-cycle progression of many types of cells is negatively regu-
lated by the series of proteins called CKIs. Therefore the effect of
NS-398 on the expression of CKIs in NA cells was investigated.
NA cells were incubated in the presence or absence of NS-398.
At 6 and 12 h after incubation, cells were lysed and CKI protein
levels were determined by Western blot analysis. p21 was slightly
expressed in untreated NA cells, and was up-regulated by NS-
398. The up-regulation of p21 became obvious at 6 and 12 h after
incubation with NS-398 (Figure 2), and was seen in longer incuba-
tion periods being tested (data not shown). Densitometrical
analysis revealed that p21 level in cells treated with NS-398 was
higher than that in untreated cells (3.2-fold higher at 6 h treat-
ment, and 1.7-fold higher at 12 h treatment) (data not shown).
The other p21 family of CKI, p27, was also detected in untreated
NA cells, but it was not up-regulated by NS-398 (Figure 2). p57
was slightly expressed in untreated NA cells. As well as p27, p57
was not up-regulated by NS-398 (data not shown). We next exam-
ined the expression of the INK4 family of CKI in NA cells in the
presence or absence of NS-398. In contrast to the p21 family of
CKI, none of them were detected in untreated NA cells, and they
were not induced by NS-398 (date not shown).
Cell-cycle analysis of NA cells after transfection of p21
phosphorothioate antisense oligonucleotides
To conﬁrm that the cell cycle arrest induced by NS-398 was due to
up-regulation of p21, we employed studies with p21 phosphor-
othioate antisense oligonucleotide. NA cells were pretreated with
p21 phosphorothioate antisense oligonucleotide (10 mM). Twenty-
four hours after incubation, cells were further incubated with or
without NS-398 for 24 h. The cell cycle distribution of these cells
was analysed by ﬂow cytometry, and the results were compared
to the cell cycle distribution of untransfected, p21 sense and
scrambled oligonucleotide transfected cells and untreated cells.
Transfection of p21 antisense oligonucleotide could induce
complete inhibition of the G0/G1 cell cycle arrest induced by
NS-398 (Table 1). Both sense (Table 1) and scrambled (data not
E
x
p
e
r
i
m
e
n
t
a
l
T
h
e
r
a
p
e
u
t
i
c
s
None NS-398
G0/G1
G2/M
S
G0/G1                      49.3                                           73.0
   S                          31.4                                           22.0
G2/M                      19.2                                             4.5 (%)
Figure 1 Effect of NS-398 on the cell cycle distribution in NA cells. NA
cells were incubated in the presence or absence of NS-398 (79.5 mM) for
24 h. Cell cycle analysis was performed as described in Materials and Meth-
ods. Results from a representative analysis are shown.
1                    2                    3                    4
         p21
         p27
     myosin
Figure 2 Western blot analysis of p21 expression in NA cells. NA cells
were incubated in the presence (lanes 3, 4) or absence (lanes 1, 2) of NS-
398 (79.5 mM). At 6 (lanes 1, 3) and 12 h (lanes 2, 4), NA cells were lysed,
and Western blot analysis was performed as described in Materials and
Methods.
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cell cycle arrest induced by NS-398. Western blot analysis showed
that treatment with p21 antisense oligonucleotides suppressed p21
protein levels in NA cells (3.34-fold reduction as determined by
densitometry), conﬁrming that p21 antisense oligonucleotide
employed here is working in NA cells.
Cell-cycle analysis of NA cells after transfection of COX-2
phosphorothioate antisense oligonucleotides
To further assess whether G0/G1 cell-cycle arrest induced by NS-
398 is associated with inhibition of COX-2 expression, NA cells
were transfected with COX-2 phosphorothioate antisense oligonu-
cleotides and the cell-cycle distribution was compared to the cell-
cycles of untransfected and COX-2 sense oligonucleotide-trans-
fected NA cells. Although the control COX-2 sense
oligonucleotide had no effect on the cell-cycle distribution of
NA cells, transfection with COX-2 antisense oligonucleotides into
NA cells was associated a with decrease in S phase population
(30.6 to 25.9%) and a increase in GO/G1 population (49.2 to
66.1%) compared with untransfected NA cells (Figure 3). Western
blot analysis showed that p21 level in COX-2 antisense-treated
cells was higher than that in sense-treated cells (data not shown).
The effect of COX-2 antisense oligonucleotides on p21 up-regula-
tion was weaker than that of NS-398. Western blot analysis
revealed that treatment with COX-2 antisense oligonucleotide
up-regulated p21 level in NA cells (2.4-fold up-regulation as
determined by densitometry). These result indicates that p21 is
really one of the downstream elements for COX-2 associated
growth suppression.
Apoptosis assay
We next examined whether the treatment with NS-398 induced
apoptotic cell death in NA cells, using two independent techniques:
annexin V afﬁnity assay, and staining with a DNA-speciﬁc dye.
It is reported that plasma membrane changes occur very early in
the cell undergoing apoptotic cell death. Recent studies indicate
that apoptotic cell death is accompanied by surface exposure of
phosphatydylserine (PS) which locates on the inner surface of
the plasma membrane, while the membrane integrity remains
unchanged. Surface exposed PS can be detected by its afﬁnity for
annexin V, a phospholipid binding protein, and it is therefore
shown to be a useful marker of early apoptoic change (von
England et al, 1998).
NA cells were incubated with NS 398 for 24, 48 and 72 h, and
cells were labelled with annexin V-FITC and PI. Flow cytometry
was performed on a FACS Calibur, and data were analysed by
the Cell Quest 3.1 software. The per cent of Annexin V positive
cells was dramatically increased by NS-398 for 24 h (from 3.9 to
28.1%) (Table 2). The per cent of Annexine V positive cells was
increased compared to control, but gradually decreased after 24 h
(data not shown).
However, treatment of NA cells with NS-398 for 24, 48 and 72 h
did not result in the appearance of typical morphological changes
of apoptosis on staining the cells with the DNA-speciﬁc ﬂuoro-
chrome bis-benzimide trihydrochloride, as demonstrated in
Figure 4.
DISCUSSION
An expanding body of information has suggested the possible
application of COX-2 selective inhibitors in cancer chemopreven-
tion. Recent studies revealed that COX-2 was overexpressed in
SCC cells, and that a selective COX-2 inhibitor suppressed prolif-
eration of SCC cell lines. This inhibition was mediated by
reduced synthesis of PGE2, which plays important roles in the
proliferation of cells. Here we showed that growth inhibition of
NA cells by NS-398 was associated with G0/G1 cell-cycle arrest.
Western blot analysis showed that NS-398 up-regulated p21
protein, a speciﬁc inhibitor of CDKs, in NA cells. Moreover,
growth inhibition induced by NS-398 was reduced in p21-antisense
treated NA cells compared to untreated NA cells. Taken together,
the accumulation in G0/G1 by NS-398 might be mediated by
up-regulation of p21.
The effect of NS-398 was speciﬁc for p21, since the expression of
other CKIs was not affected by NS-398. The expression of D-type
cyclins (cyclin D1, D2, D3) and their associating kinases (CDK2
and 4), which allow cells to pass the G1 checkpoint, were also
not altered by NS-398 in NA cells (data not shown). Recent study
has demonstrated that NS-398 induced G1 growth arrest in A549
lung cancer cells. NS-398 speciﬁcally up-regulated cyclin-dependent
kinase inhibitor p27, whereas the expression of G1 cyclins and
CDKs were not changed (Hung et al, 2000). These results were
not consistent with our results. Further investigation should be
necessary to elucidate these inconsistencies.
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Table 1 Effect of p21 phosphorothioate antisense oligonucleotide on
the cell cycle distribution on NA cells
Cell cycle None Antisense Sense
G0/G1 49.7+4.9 70.0+2.1 47.5+0.9 50.0+1.9 52.9+1.0 69.1+3.3
S 22.9+0.8 15.6+1.7 25.2+2.4 25.3+3.0 18.4+3.2 12.6+1.7
G2/M 26.2+5.0 13.9+0.6 25.2+2.1 22.8+2.5 27.3+2.0 18.7+2.0
NS-398 (7) (+) (7) (+) (7) (+)
NA cells were transfected with p21 phosphorothioate antisense or sense oligonu-
cleotide (10 mM). Twenty hours after incubation, cells were incubated with or
without NS-3098 (79.5 mM) for 24 h. Cell cycle anlaysis was determined as
described in Materials and Methods. Data shown in Table 1 are the mean+s.d. of
triplicate determinations.
None Antisense Sense
G0/G1
G2/M
S
G0/G1              49.2                         66.1                         52.0
   S                  30.6                         25.9                         30.2
G2/M               20.3                           8.1                         17.8 (%)
Figure 3 Effect of COX-2 phosphorothioate antisense oligonucleotide
on the cell cycle distribution of NA cells. NA cells were transfected with
COX-2 phosphorothioate antisense or sense oligonucleotide (10 mM) for
24 h. Cell cycle analysis was performed as described in Materials and Meth-
ods. Results from a representative analysis are shown.
Table 2 Effect of NS-398 on the binding of annexin V on NA cells
Annexin V expression (%)
Negative Positive
None 94.0 3.9
NS-398 71.9 28.1
NA cells were incubated with or without NS-398 (75.9 mM) for 24 h. Annexin V
assay was determined as described in Materials and Methods. Results from a
representative analysis are shown.
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remains to be examined. The p21 protein was identiﬁed originally
as a gene that can be directly regulated by the tumor suppressor
protein p53 (El-Deiry et al, 1994; Hunter and Pines, 1994; Sherr
and Roberts 1995; Harper and Elledge, 1996). The expression of
p21 is stimulated by a variety of external stimuli, such as various
growth factors, cytokines, tumor promoters and DNA damaging
agents (El-Deiry et al, 1994; Sheikh et al, 1994). However not all
stimulatory pathways involve the p53 protein, as some of the
agents are also able to induce p21 expression in p53-negative cells
(Michieli et al, 1994; El-Deiry et al, 1995; Parker et al, 1995; Alpan
and Pardee 1996; Li et al, 1995; Liu et al, 1996; Zeng and El-Deiry,
1996; Prowse et al, 1997). DNA sequence analysis of exons 2 to 11
of the p53 gene revealed one missense mutation in exon 6 (codon
220, Tyr to Hys) of NA cells (data not shown). Codon 220 is
located at the DNA binding domain of p53 gene, and this muta-
tion appears to inhibit speciﬁc DNA binding (Gottlieb and Oren,
1996). Accordingly, the up-regulation of p21 in NS-398-treated
NA cells might be mediated by a p53-independent pathway.
Evidence suggests that the increase in tumorigenic potential by
COX-2 overexpression is associated with resistance to apoptosis
(Tsuji and Dubois, 1995). Selective inhibitors of COX-2 have been
demonstrated to induce apoptosis in a variety of cancer cells,
including those of the colon, stomach, prostate and breast. These
observations are consistent with the COX-2 inhibitor being a
chemopreventive agent that increases the susceptibility of cancer
cells to apoptosis. However, NS-398 could only induce a very early
stage of apoptosis (detection of annexin V) in NA cells, and it
could not induce morphological change (nuclear fragmentation)
which was related to apoptotic cell death. To further investigate
the effect of NS-398 on apoptotic process in NA cells, NA cells
were incubated with or without NS-398 for 6, 12 and 24 h, and
caspase activities (caspases 1, 3 6, 8 and 9) were measured using
speciﬁc ELISA (Medical and Biological Laboratories, Tokyo,
Japan). No caspase activities were induced by NS-398 (data not
shown). These results suggest that COX-2 inhibitor is not sufﬁcient
to complete the whole process of apoptosis in SCC cells. The
reason why COX-2 inhibitor cannot induce apoptotic cell death
in NA cells remains elusive. Considering the molecular basis for
COX-2 inhibitor-induced apoptosis, it has been proposed that it
might be due to the down-regulation of Bcl-2 expression (Liu et
al, 1998; Sheng et al, 1998). It has also reported that apoptotic
effect of celecoxib, a selective COX-2 inhibitor, is partly mediated
by blocking the activation of the anti-apoptotic kinase AKT (Hsu et
al, 2000). However, neither down regulation of Bcl-2 or blocking
activation of AKT was observed in NS-398 treated NA cells (data
not shown).
It is generally accepted that COX-2 inhibitors exert their action
via blocking PG synthesis by direct COX inhibition. However,
whether COX-2 inhibitors block proliferation of cancer cells solely
by blocking PG synthesis is a matter still being discussed. Several
studies have shown that COX-2 inhibitors can act through
mechanisms that are independent of their ability to inhibit COX-
2. For example, celecoxib, a selective COX-2 inhibitor, induced
apoptosis of a prostate cancer cell line through a target other than
COX-2 (Hsu et al, 2000). COX-2 inhibited cell cycle progression in
a variety of cell types by a novel mechanism that did not require
the synthesis of PG (Trifan et al, 1999). Recently we have shown
that NS-398 inhibits the proliferation and differentiation of human
leukemia cell lines via PG-independent pathways (Nakanishi et al,
2001). Therefore, it is indicated that selective COX-2 inhibitors also
possess COX-2 independent pathways which are responsible for
their functions. When NA cells were treated with COX-2 antisense
oligonucleotide, the cell cycle distribution of NA cells was accumu-
lated to G0/G1. Moreover, the degree of suppression of
proliferation with NS-398 was almost the same as that with
COX-2 antisense oligonucleotide. This result indicates that accu-
mulation in G0/G1 by NS-398 is via decreased PG biosynthesis
resulting from down-regulation of COX-2 expression, since PGE2
induced proliferation of NA cells (Sumitani et al, 2001). Further
investigations are required to identify, at a molecular level, the
mechanism of the cell-cycle arrest by COX-2 inhibitor, and to
assess its clinical relevance.
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Figure 4 Nuclei of NS-398-treated NA cells. NA cells were incubated in
the presence (B) or absence (A) of NS-398 for 24 h. Apoptoic cell death
was detected as described in Materials and Methods. NA cells treated with
apoptosis inducing agent (NOC12, nitric oxide donor) for 24 h are shown
as a positive control (C).
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